Xetra

DGAP-News: Nanogate SE: Xetra trading of Nanogate share expired - tradability of the share on other stock exchanges secured

Retrieved on: 
Tuesday, March 23, 2021
Deutsche Börse, Cities in Germany, Frankfurt, Futures exchanges, Finance, Eurex Exchange, Xetra, Financial markets, Frankfurt Stock Exchange, Stock exchange, Open outcry, Rudolf Ferscha

As of today, the Nanogate SE share is listed exclusively in floor trading on the Frankfurt Stock Exchange and on other stock exchanges.

Key Points: 
  • As of today, the Nanogate SE share is listed exclusively in floor trading on the Frankfurt Stock Exchange and on other stock exchanges.
  • The Xetra listing, on the other hand, has expired.
  • The background to this is that the Nanogate share - like many other stocks - is no longer classified as CCP-capable by EUREX Clearing.
  • Nanogate (ISIN DE000A0JKHC9) is a leading global technology company for design-oriented, multifunctional components and surfaces.

DGAP-News: Advanced Blockchain AG sets up Stela Labs, a Smart Contract Auditing and Development Company

Retrieved on: 
Wednesday, March 17, 2021
Cryptocurrencies, Blockchains, Articles, Technology, Computing, Computer law, Contract law, Smart contract, Ethereum, Xetra

Advanced Blockchain AG sets up Stela Labs, a Smart Contract Auditing and Development Company

Key Points: 
  • Advanced Blockchain AG sets up Stela Labs, a Smart Contract Auditing and Development Company
    The issuer is solely responsible for the content of this announcement.
  • Advanced Blockchain AG (Frankfurt, Primary Market Dsseldorf, XETRA: ISIN DE000A0M93V6) announces that it initiates Stela Labs, an auditing and development company for Web 3.0 infrastructure.
  • Stela Labs brings together a diverse and experienced team of blockchain pioneers and engineers to fulfill these functions, implementing a comprehensive smart contract auditing and protocol building strategy.
  • Additional information on Advanced Blockchain AG, Stela Labs, and its other projects can be found at www.advancedblockchain.com .

Newron Announces 2020 Financial Results and Provides Outlook For 2021

Retrieved on: 
Tuesday, March 16, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Sodium channel blockers, Calcium channel blockers, Monoamine oxidase inhibitors, Drugs, Safinamide, Zambon, Branches of biology, Xetra, XEWW-AM, Psychoactive drugs

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newrons business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newrons extensive experience in the development of Xadago/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: Newron announces 2020 financial results and provides outlook for 2021

Retrieved on: 
Tuesday, March 16, 2021
Sodium channel blockers, Calcium channel blockers, Monoamine oxidase inhibitors, Drugs, Safinamide, Zambon, Branches of biology, Xetra, Psychoactive drugs

Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    "The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newron's business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newron's extensive experience in the development of Xadago(R)/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: AlzChem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 4th Interim report

Retrieved on: 
Monday, March 15, 2021
Financial markets, Finance, Stock market, Companies, ODDO BHF, Buyback, Xetra, Share repurchase, ING Group

In the period from March 8, 2021 up to and including March 12, 2021, a total of 370 shares of AlzChem Group AG were acquired as part of the share buyback program announced on February 2, 2021.

Key Points: 
  • In the period from March 8, 2021 up to and including March 12, 2021, a total of 370 shares of AlzChem Group AG were acquired as part of the share buyback program announced on February 2, 2021.
  • The total number of shares acquired to date as part of this buyback amounts to 11.933.
  • The acquisition was carried out by ODDO BHF Aktiengesellschaft, Frankfurt am Main/Germany via the stock exchange (XETRA) on behalf of AlzChem Group AG.
  • The total number of repurchased shares, the weighted average price and the aggregated volume per day were as follows:

DGAP-News: Advanced Blockchain AG makes Fei Protocol Investment

Retrieved on: 
Thursday, March 11, 2021
Cryptocurrencies, Articles, Technology, Payment systems, Blockchain, Stablecoin, Xetra, Coinbase

Advanced Blockchain AG (Frankfurt, Primary Market Dsseldorf, XETRA: ISIN DE000A0M93V6) has made an investment into the Fei Protocol ( https://fei.money/ ).

Key Points: 
  • Advanced Blockchain AG (Frankfurt, Primary Market Dsseldorf, XETRA: ISIN DE000A0M93V6) has made an investment into the Fei Protocol ( https://fei.money/ ).
  • This investment was made through nakamo.to in the same round as Coinbase and other prominent investors, in a united effort to support this promising new stablecoin project.
  • With this investment into the Fei Protocol, Advanced Blockchain supports the development and use of an improved stablecoin model, that is positioned to price stability without compromising on decentralization.
  • Thus, this investment helps Advanced Blockchain uphold its mission of promoting user-centric, cutting-edge blockchain solutions.

Northern Data AG appoints Jens-Philipp Briemle as Head of Investor Relations

Retrieved on: 
Wednesday, March 10, 2021
Software, Networks, Finance, Hardware, Banking, Data management, Professional services, Technology, Finance, Money, Financial markets, Gerresheimer, MDAX, Xetra, DAX, Investor relations, Prospectus

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) has appointed Jens-Philipp Briemle as Head of Investor Relations to further strengthen its Investor Relations activities.

Key Points: 
  • Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) has appointed Jens-Philipp Briemle as Head of Investor Relations to further strengthen its Investor Relations activities.
  • He joins Northern Data from MDAX-listed Gerresheimer AG, a leading international provider of high-quality primary packaging where he was heading the IR department.
  • Jens-Philipp Briemle, Head of Investor Relations at Northern Data: "I am joining Northern Data with great enthusiasm.
  • This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG.

DGAP-News: Northern Data AG appoints Jens-Philipp Briemle as Head of Investor Relations

Retrieved on: 
Wednesday, March 10, 2021
Finance, Money, Gerresheimer, MDAX, Economy, DAX, Xetra, Frankfurt, Xetra, Investor relations, IR

Frankfurt am Main - March 10, 2021 - Northern Data AG (XETRA: NB2 , ISIN: DE000A0SMU87 ) has appointed Jens-Philipp Briemle as Head of Investor Relations to further strengthen its Investor Relations activities.

Key Points: 
  • Frankfurt am Main - March 10, 2021 - Northern Data AG (XETRA: NB2 , ISIN: DE000A0SMU87 ) has appointed Jens-Philipp Briemle as Head of Investor Relations to further strengthen its Investor Relations activities.
  • Heading the Company's strategic communications to enhance Northern Data AG's global positioning in the capital markets, Jens-Philipp Briemle will report directly to CEO Aroosh Thillainathan.
  • He joins Northern Data from MDAX-listed Gerresheimer AG, a leading international provider of high-quality primary packaging where he was heading the IR department.
  • Jens-Philipp Briemle, Head of Investor Relations at Northern Data: "I am joining Northern Data with great enthusiasm.

The NAGA Group AG Closes USD 30 Million Financing Framework and Reports Record Growth

Retrieved on: 
Tuesday, March 9, 2021
Social media, Communications, Professional services, Finance, Xetra, Benjamin Bilski, Xetra, Businesspeople, German people

The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports on the largest financing arrangement in the company's history to date and further record growth in February 2021.

Key Points: 
  • The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports on the largest financing arrangement in the company's history to date and further record growth in February 2021.
  • NAGA has signed an agreement with the US Fund Yorkville Advisors securing a growth financing framework of up to USD 30 million.
  • The financing gives us the power and the flexibility to allow the company to be taken to the next level.
  • This decade will be definitely the breakthrough period for FinTechs", comments NAGA CEO Benjamin Bilski on the closed deal.

DGAP-News: The NAGA Group AG closes USD 30 million financing framework and reports record growth

Retrieved on: 
Tuesday, March 9, 2021
Xetra, Naga, Xetra

Hamburg, 09.03.2021 - The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports on the largest financing arrangement in the company's history to date and further record growth in February 2021.

Key Points: 
  • Hamburg, 09.03.2021 - The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports on the largest financing arrangement in the company's history to date and further record growth in February 2021.
  • NAGA has signed an agreement with the US Fund Yorkville Advisors securing a growth financing framework of up to USD 30 million.
  • "We are excited about the deal with Yorkville and are setting the course for NAGA to scale even faster.
  • The financing gives us the power and the flexibility to allow the company to be taken to the next level.